Trial Profile
A Multi-center, Observational, Non-interventional, Post-authorisation Safety Study of Patients with Relapsed/Refractory Multiple Myeloma in European Union
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2018
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Pomalidomide (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms EU PASS
- 17 Jun 2018 Results (n=3630) presented at the 23rd Congress of the European Haematology Association.
- 25 Jun 2017 Results (n=3630, data cut off March 1, 2016) presented at the 22nd Congress of the European Haematology Association
- 06 Dec 2016 Results (n=218) assessing the safety of Pomalidomide, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology